21 September 2026 · The Pharmacist
Reformed National Cancer Board meets as key targets missed
The reformed National Cancer Board has met for the first time to oversee and scrutinise progress on achieving faster diagnosis and treatment pathways for cancer patients across the NHS. The board has been reconstituted at a time when healthcare providers have faced ongoing challenges in meeting key performance targets related to cancer care.
The leadership of the reformed body is split between independent health policy expertise and NHS England leadership. It is co-chaired by Anita Charlesworth, a health economist who holds a role as a non-executive director at the West and North London integrated care board, and Mark Cubbon, who serves as NHS England's national director for cancer. Together, the co-chairs will guide the board's review of cancer care timelines and target delivery across the health service.
Limited information has been published regarding the detailed agenda, specific workstreams, or any new clinical guidance resulting from this inaugural meeting. As a result, the precise mechanisms through which the board will monitor diagnostic pathways and treatment acceleration remain unspecified in the current update, beyond the overarching objective to address missed national targets and improve patient timelines.
For UK online pharmacies and health platforms, any eventual changes to NHS diagnostic and referral frameworks will need to be monitored, though the direct operational impact remains uncertain at this stage.